 The Global Alliance for Progress (GAP) in hemophilia is a 10-year healthcare development project, launched in April 2003. GAP’s goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.
The project aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with hemophilia, and the gap between the amount of treatment product needed versus what is available.
GAP partners include Baxter, Bayer, the Irish Hemophilia Society, the Jan Willem André de la Porte Family Foundation, the World Health Organization (WHO), Wyeth, and ZLB Behring.
GAP country programs are designed to improve five main areas: government support, the care delivery system, medical expertise and diagnosis, quality and quantity of treatment products, and the national hemophilia organization.
The first GAP countries were Egypt, Georgia, Mexico, and the Philippines, followed by Armenia, Russia, and Thailand. Azerbaijan and Jordan then joined the project in 2005 and Lebanon in 2006. There are presently 10 ongoing GAP countries.
GAP training, education, and information materials also reach out to the entire hemophilia community. Several other countries are accessing GAP information on the WFH web site to implement their own development projects, using the tools and model developed by the Federation.
Steps for Developing National Hemophilia Care Programs
For more information on GAP, contact Antonio Almeida at aalmeida@wfh.org.
Resources
The WFH thanks the following organizations for their valuable support of the GAP program.
Founding sponsor:
Sustaining sponsors:
- The André de la Porte Family Foundation
Supporting sponsors:
Supporters:
- Irish Haemophilia Society
- World Health Organization
Last Updated June 2006 |
